EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Treatment of Behçet disease with oral roflumilast: an observational study

Rodrigo Peñuelas Leal iD, Carolina Labrandero Hoyos iD, Jose Amancio Peñuelas Ruiz, Leticia Bagán iD, Violeta Zaragoza Ninet, Jose Luis Sánchez Carazo, Gemma Pérez Pastor, Andrés Grau Echevarría iD, Altea Esteve Martínez, Malena Finello iD, Daniel Blaya Imbernon iD, Víctor Dios Guillán und 3 weitere

Clinical and Experimental Dermatology · 2024

DOI: 10.1093/ced/llae284 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Rodrigo Peñuelas Leal und 14 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Cyclopropanes, Aminopyridines, Behcet Syndrome, Benzamides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Spanish Academy of Dermatology and Venereology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mucocutaneous Behçet disease often presents a therapeutic challenge. Roflumilast has shown promise in the treatment of other inflammatory dermatological conditions.

Objectives

The objective of this study was to evaluate the characteristics, effectiveness and safety of roflumilast in the treatment of Behçet disease-associated aphthosis in routine clinical practice.

Methods

We performed a single-cohort ambispective observational study. Eleven patients with Behçet disease treated with roflumilast participated. Data collection included demographic, clinical and outcome variables. Statistical analysis compared 12 weeks of treatment with roflumilast with a previous period without treatment and with a period when the previous treatment was used.

Results

During treatment with roflumilast, a reduction in flare-ups and oral ulcers was observed compared with the untreated period and the previous treatment period. A reduction in genital ulcers, pain and ulcer duration was observed between the without treatment period and the roflumilast treatment period. Adverse effects occurred in 54% of patients, most of which were self-limiting or manageable with dose adjustment. No patients withdrew treatment.

Conclusions

Roflumilast appears to be a potential option in the treatment of Behçet disease with favourable effectiveness, safety and tolerability profiles. Although further research is needed, roflumilast offers a promising treatment option for Behçet disease-associated aphthosis, which could improve the patients’ quality of life and address unmet therapeutic needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclopropanesAminopyridinesBehcet SyndromeBenzamidesPhosphodiesterase 4 InhibitorsHumansMaleFemaleAdultMiddle AgedOral UlcerTreatment OutcomeAdministration, OralYoung AdultStomatitis, AphthousSymptom Flare Up

Substanzen

CyclopropanesRoflumilastAminopyridinesBenzamidesPhosphodiesterase 4 Inhibitors

Autor:innen und Institutionen

  • Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain.
  • Gandia Public Health Centre, Gandía, Spain.
  • Clínica Odontológica de Medicina Buccal, Valencia, Spain.
  • Oral Medicine Department, University of Valencia, Valencia, Spain.
  • Hospital Puerta del Mar, Cádiz, Spain.
  • Department of Oral and Maxillofacial Surgery, Consorci Hospital General Universitari de Valencia, Valencia, Spain.

ORCID-Profile: Rodrigo Peñuelas Leal, Carolina Labrandero Hoyos, Leticia Bagán, Andrés Grau Echevarría, Malena Finello, Daniel Blaya Imbernon, José Bagán

Förderung

  • Spanish Academy of Dermatology and Venereology

Zitieren

APA

Peñuelas Leal, R., Labrandero Hoyos, C., Peñuelas Ruiz, J. A., Bagán, L., Zaragoza Ninet, V., Sánchez Carazo, J. L., Pérez Pastor, G., Grau Echevarría, A., Esteve Martínez, A., Finello, M., Blaya Imbernon, D., Dios Guillán, V., Aguilar González, L., Bagán, J., & Alegre De Miquel, V. (2024). Treatment of Behçet disease with oral roflumilast: an observational study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae284

Vancouver

Peñuelas Leal R, Labrandero Hoyos C, Peñuelas Ruiz JA, Bagán L, Zaragoza Ninet V, Sánchez Carazo JL, et al. Treatment of Behçet disease with oral roflumilast: an observational study. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae284

BibTeX
@article{PeuelasLeal2024,
  author = {Peñuelas Leal, Rodrigo and Labrandero Hoyos, Carolina and Peñuelas Ruiz, Jose Amancio and Bagán, Leticia and Zaragoza Ninet, Violeta and Sánchez Carazo, Jose Luis and Pérez Pastor, Gemma and Grau Echevarría, Andrés and Esteve Martínez, Altea and Finello, Malena and Blaya Imbernon, Daniel and Dios Guillán, Víctor and Aguilar González, Lucía and Bagán, José and Alegre De Miquel, Victor},
  title = {Treatment of Behçet disease with oral roflumilast: an observational study},
  journal = {Clinical and Experimental Dermatology},
  year = {2024},
  doi = {10.1093/ced/llae284}
}
Kostenlos starten →